3Q 2017 Earnings Announcement | Spero Therapeutics, Inc.

About
Pipeline
Antibiotic Resistance
Partners
Investors & Media
Careers
Contact

3Q 2017 Earnings Announcement

Overview
News Releases
Spero in the News
Events & Presentations
- Upcoming & Past Events
Stock Information
Corporate Governance
SEC Filings
IR Resources

3Q 2017 Earnings Announcement

Dec 14, 2017

Print Page

Print Page
RSS Feeds

RSS Feeds
Email Alerts

Email Alerts
Contact IR

Contact IR

About

Management Team
Board of Directors
Contact

Pipeline

Tebipenem HBr: Oral Gram-Negative Program
SPR720: Non-tuberculosis Mycobacterium
SPR206: Direct Acting IV Potentiator
Key Publications and Presentations

Antibiotic Resistance

Partners

Investors & Media

Overview
News Releases
Spero in the News
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
IR Resources

Careers

©2020 Spero Therapeutics All Rights Reserved

Privacy Policy
Terms of Use